Literature DB >> 11003204

Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.

M E McCaul1, G S Wand, C Rohde, S M Lee.   

Abstract

BACKGROUND: There is strong evidence for the role of the endogenous opioid system in alcohol reinforcement and consumption; however, recent human laboratory studies and clinical trials have reported mixed effects of naltrexone (a nonselective opioid antagonist) on alcohol-related behaviors. This paper reports a secondary data analysis of a human laboratory study that examines the relationship between serum levels of 6-beta-naltrexol, the major, biologically active metabolite of naltrexone, and subjective effects of alcohol.
METHODS: The study used a within-subjects design to examine the effects of naltrexone (0, 50, and 100 mg/day) on subjective responses to alcohol (none, moderate, and high dose) in heavy drinkers (n = 23). Each subject received three doses of naltrexone in random order; each naltrexone dose was administered over an 8 day period on an inpatient unit, with a 1 week outpatient washout between doses. After stabilization at each of the naltrexone doses, subjects participated in three alcohol challenge sessions (none, moderate, and high dose) in random order; thus, each subject participated in a total of nine alcohol administration sessions.
RESULTS: Doubling the naltrexone dose (50 vs. 100 mg/day) doubled the mean serum 6-beta-naltrexol levels. At each naltrexone dose, there was a 4-fold range in 6-beta-naltrexol levels across subjects. Before alcohol administration, higher 6-beta-naltrexol levels were associated with higher ratings of sedation. After high-dose alcohol administration, higher 6-beta-naltrexol levels were associated with significantly lower ratings of liking and best effects.
CONCLUSIONS: These findings provide further evidence of the involvement of the opioid system in the modulation of alcohol effects and suggest that serum 6-beta-naltrexol concentrations may be important in predicting therapeutic response to naltrexone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11003204

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  13 in total

1.  Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.

Authors:  Stephanie S O'Malley; Suchitra Krishnan-Sarin; Sherry A McKee; Robert F Leeman; Ned L Cooney; Boris Meandzija; Ran Wu; Robert W Makuch
Journal:  Int J Neuropsychopharmacol       Date:  2008-09-17       Impact factor: 5.176

2.  A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder.

Authors:  Andrea C King; Deborah Hasin; Sean J O'Connor; Patrick J McNamara; Dingcai Cao
Journal:  Biol Psychiatry       Date:  2015-05-14       Impact factor: 13.382

3.  Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.

Authors:  Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Xiaoqiang Xu; J James Frost; Dean F Wong; Mary E McCaul
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

4.  A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention.

Authors:  David W Oslin; Kevin G Lynch; Helen M Pettinati; Kyle M Kampman; Peter Gariti; Lois Gelfand; Thomas Ten Have; Shoshana Wortman; William Dundon; Charles Dackis; Joseph R Volpicelli; Charles P O'Brien
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

Review 5.  Improving clinical outcomes for naltrexone as a management of problem alcohol use.

Authors:  Gary K Hulse
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

6.  In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs.

Authors:  Paul K Kiptoo; Kalpana S Paudel; Dana C Hammell; Mohamed O Hamad; Peter A Crooks; Audra L Stinchcomb
Journal:  Eur J Pharm Sci       Date:  2008-01-31       Impact factor: 4.384

7.  Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin.

Authors:  Priyanka Ghosh; DoMin Lee; Kyung Bo Kim; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2013-08-14       Impact factor: 4.200

8.  Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs.

Authors:  Stan L Banks; Raghotham R Pinninti; Harvinder S Gill; Kalpana S Paudel; Peter A Crooks; Nicole K Brogden; Mark R Prausnitz; Audra L Stinchcomb
Journal:  J Pharm Sci       Date:  2010-07       Impact factor: 3.534

9.  Attenuation of cocaine and heroin seeking by μ-opioid receptor antagonism.

Authors:  Chiara Giuliano; Trevor W Robbins; David R Wille; Edward T Bullmore; Barry J Everitt
Journal:  Psychopharmacology (Berl)       Date:  2013-01-09       Impact factor: 4.530

10.  Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.

Authors:  Jarred W Younger; Alex J Zautra; Eric T Cummins
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.